Biopharmaceutical firm Neurocrine Biosciences Inc. announced earnings results for the third quarter of 2015.

The company reported a net loss of $34.4 million, or $0.40 loss per share, compared with a net loss of $15.9 million, or $0.21 loss per share, for the same period in 2014.

Research and development expenses were $24.4 million during the third quarter of 2015 compared with $12.2 million for the same period in 2014.

The company's balance sheet at September 30, 2015 reflected total assets of $492.4 million, including cash, cash equivalents, investments and receivables of $481.7 million.

Neurocrine Biosciences discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The company’s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine has 11 programs in various stages of research and development, including six programs in clinical development.